GT Biopharma
NASDAQ: GTBPSan Francisco, US · Delaware corporation
GT Biopharma develops immuno-oncology biopharmaceutical drugs using its proprietary platform technology, targeting cancers including acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and solid tumors. The company operates in the immunotherapy and oncology drug development sector.
Founders & leadership
MB
Michael BreenExecutive
AU
Alan UrbanExecutive
AC
Anthony CataldoExecutive
SW
Steven WeldonExecutive
AD
Anshuman DubeResigned on July 25, 2014
DS
David SaloffResigned on July 25, 2014
KE
Kenneth EatonNamed on SEC filing
Board
BW
Bruce WendelBoard director
CC
Charles CasamentoBoard director
RS
Rajesh ShrotriyaBoard director
Reported raises · per SEC filings
Form D private placements$33.5M disclosed across 9 of 10 rounds · 2014–2025
▶$20MofferedMay 2025 · 2 investors · BiotechnologyRule 506(b)
▶$20MofferedMay 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BreenExecutive Officer, Director
- Alan UrbanExecutive Officer
- Hilary KramerDirector
- Charles CasamentoDirector
- Andrew RitterDirector
- Offering amount
- $20M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedMay 2025 · 9 investors · BiotechnologyRule 506(b)
▶$6MraisedMay 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles CasamentoDirector
- Alan UrbanExecutive Officer
- Hilary KramerDirector
- Michael BreenExecutive Officer
- Andrew RitterDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMar 2025 · 6 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMar 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce WendelDirector
- Charles CasamentoDirector
- Michael BreenExecutive Officer, Director
- Rajesh ShrotriyaDirector
- Alan UrbanExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Sales commissions
- $70K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedJul 2020 · 18 investors · BiotechnologyRule 506(b)
▶$5.6MraisedJul 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven WeldonDirector
- Anthony CataldoDirector, Executive Officer
- Amount sold
- $5.6M
- Proceeds to insiders
- $250K
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedAug 2018 · 13 investors · BiotechnologyRule 506(b)
▶$5.1MraisedAug 2018 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathleen Clarence-SmithDirector
- Steven WeldonDirector, Executive Officer
- Anthony J. CataldoDirector
- Jon BonfiglioDirector
- Raymond UrbanskiExecutive Officer
- Peter KienerDirector
- Geoffrey B. DavisDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Aug 2018
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$7.1MraisedFeb 2018 · 14 investors · BiotechnologyRule 506(b)
▶$7.1MraisedFeb 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey B. DavisDirector
- Kathleen Clarence-SmithDirector, Executive Officer
- Anthony J. CataldoDirector
- Steven WeldonDirector, Executive Officer
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- First sale
- Jan 2018
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$4.5MraisedSep 2017 · 9 investors · BiotechnologyRule 506(b)
▶$4.5MraisedSep 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony CataldoExecutive Officer, Director
- Steven WeldonExecutive Officer, Director
- Kathleen Clarence-SmithExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Minimum investment
- $1K
- Proceeds to insiders
- $450K
- First sale
- Aug 2016
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$500KraisedJul 2015 · 2 investors · BiotechnologyRule 506(b)
▶$500KraisedJul 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven WeldonExecutive Officer, Director
- Anthony CataldoExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $500K
- Minimum investment
- $1K
- Proceeds to insiders
- $300K
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Robinhood39 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha38 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits29 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
TradingView29 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Simply Wall St28 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Public28 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Perplexity28 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with GT Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does GT Biopharma do?
- GT Biopharma develops immuno-oncology biopharmaceutical drugs using its proprietary platform technology, targeting cancers including acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and solid tumors. The company operates in the immunotherapy and oncology drug development sector.
- How much funding has GT Biopharma raised?
- GT Biopharma has disclosed $33.5M raised across 9 of its 10 known rounds.
- Where is GT Biopharma headquartered?
- GT Biopharma is headquartered in San Francisco, US.